Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
International Association for the Treatment of Sexual Offenders two people need to have a strong relationship in order for the offenders to trust the clinicians), break up and mechanistic treatment delivery. The goals of sexual offender treatment is to achieve a goal that the offender has been working toward, which most of the time the goal is to not reoffend. This can be achieved by giving them hope, gaining self-esteem, making goals, creating strong relationships, and also working with the offender regularly. When it comes to the general criminal population treatment focuses on risk, need, and responsivity. However, when applied to sexual offenders two problems are risk assessment